Subsection 56(1) Exemptions under the Controlled Drugs and Substances Act

Description

The Controlled Drugs and Substances Act (CDSA) prohibits the possession, import, export, production and distribution of controlled substances and precursors, except where explicitly authorized by the CDSA, its regulations or a specific exemption.

The CDSA contains a Ministerial authority to grant exemptions allowing the possession and use of a controlled substance or precursor chemical in a context not normally permitted by law (CDSA subsection 56(1)). Exemptions may be granted for a medical or scientific purpose, or if otherwise in the public interest. The Office of Controlled Substances (OCS) in Health Canada (HC) reviews applications, issues exemptions, and/or supports the decision maker regarding subsection 56(1) exemptions.

Why a privacy impact assessment was completed

In accordance with Appendix C of the Directive on Privacy Practices, a Privacy Impact Assessment (PIA) was conducted on the legacy programs within the Office of Controlled Substances, including the issuance of s56(1) exemptions, as this program involves the collection, use, disclosure, retention and disposal of personal information as part of the intake, assessment, and decision-making process for exemption requests.

Compliance and enforcement activities, and the handling of personal information by experts elsewhere in HC or in other government institutions during the consultation process, are out of scope. 

Additional information

The assessment identified key areas where privacy measures could be strengthened, summarized into the following considerations:

For more information about this privacy impact assessment

If you would like more information about this PIA, contact the Office of Controlled Substances at ocs-bsc@hc-sc.gc.ca

Page details

2025-12-19